Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine
Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine
批准号:
9316990
负责人:
Ravinder Kaur
金额:
$8.48万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-13 至 2019-06-30
关键词:
AcuteAddressAdoptedAdultAdvisory CommitteesAgeAntibioticsAntibodiesAntibody ResponseBacteremiaBlood specimenCD4 Positive T LymphocytesCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeChildClinical ResearchClinical TrialsConjugate VaccinesCountryDataDiseaseDoseEpidemiologyEuropeEuropeanFoundationsFutureGenerationsHaemophilus influenzae type b bacteriaHealth PolicyHelper-Inducer T-LymphocyteHumanImmuneImmune responseImmunizationImmunization ScheduleImmunoglobulin GImmunologic MemoryImmunologicsInfantKnowledgeLicensureLifeMeasuresMemoryMemory B-LymphocyteMeningitisOperative Surgical ProceduresOrganizational PolicyOtitisOtitis MediaPathogenesisPediatricsPlasmaPneumococcal 7-Valent Conjugate VaccinePneumococcal InfectionsPneumococcal conjugate vaccinePneumoniaPoliciesPolysaccharidesPreventionProcessProductionPublic HealthRecommendationRoleSamplingScheduleSerotypingSinusitisStreptococcus pneumoniaeT memory cellT-LymphocyteTechnologyTimeTubeTympanostomyUnited States National Institutes of HealthUpdateVaccinationVaccinesWorld Health Organizationagedbaseburden of illnessclinically relevantcohortcostdisorder preventionexperienceimmunogenicitylow income countrymemory CD4 T lymphocytemicrobiomenovelpreventprospectiveresponsevaccination scheduleworking group
中文摘要
文摘:
英文摘要
Abstract:
The recent World Health Organization policy statement on pneumococcal conjugate vaccines
(PCVs) endorsed a schedule of 3 primary doses without a booster (3p+0 schedule) or, as a new
alternative, 2 primary doses with a booster dose (2p+1 schedule) considering the cost for low-
income countries.
PCV13 was licensed in the U.S. for 3 primary doses plus a booster (3p+1 schedule) supported
by high efficacy demonstrated by 2 large scales US-based clinical trials. A clear understanding
of the full impact of reduced-dose schedules of PCV on protective antibody levels and
functionality as well as induction of immunologic B- and T- cell memory is lacking. This study will
determine specific immune responses of children receiving 2 primary doses, 3 primary doses
and 3p+1 doses of PCV13 and provide for the first time direct comparison of IgG antibody
levels, functional antibody differences and cellular immune memory differences in the same
cohort of children.
Clinically relevant significant differences in levels of antibodies, functional antibodies, and
memory B-cell and CD4+ T-cell responses can be measured after 2 compared to 3 primary
doses of PCV13 and a booster dose in the second year of life that stimulates clinically relevant
increases in antibodies, memory B-cell and CD4+ T-cell responses. We will explore this
hypothesis by comparing immune responses in prospectively collected blood samples from
infants after 2p vs. 3p doses of PCV13 and pre vs. post booster PCV13. Prospectively collected
blood samples of children at 4 time points after PCV13 doses will be analyzed to quantitate
differences in immune responses. Healthy children aged 6-18 months from Rochester, NY, USA
will have samples of plasma and immune cells studied after PCV13 doses. The study will
provide a novel assessment of antibody levels and functionality as well as B- and T-cell memory
immune responses against all PCV13 serotypes following 2p vs. 3p doses and pre vs. post booster
doses in children. Remarkably few studies have looked at the antibody responses against all 13
polysaccharides in one cohort of children and none have simultaneously focused on examination of B-
and T-cell specific memory. The findings will strengthen or bring to question policy decisions impacting
children worldwide regarding recommendations for PCV administration schedules. Understanding
the impact of each dose of PCV13 to generate replenished memory B-cell pool and T helper
cells will provide valuable information to assess any changes in immunization schedules.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae
-
批准号:10042550
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2020
-
负责人:Ravinder Kaur
-
依托单位:
Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae
-
批准号:10245160
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2020
-
负责人:Ravinder Kaur
-
依托单位:
海外基金